Abstract
Recently, we have shown that a novel recombinant bispecific single-chain antibody construct (bscCD19 × CD3), induces highly efficacious lymphoma-directed cytotoxicity mediated by unstimulated peripheral T lymphocytes. Functional analysis of bscCD193CD3 has so far been exclusively performed with human B lymphoma cell lines and T cells from healthy donors. Here we analysed the properties of bscCD193CD3 using primary B cells and autologous T cells from healthy volunteers or patients with B-cell chronic lymphocytic leukaemia (B-CLL). We show that bscCD193CD3 induces T-cell-mediated depletion of nonmalignant B cells in all four cases and depletion of primary lymphoma cells in 22 out of 25 cases. This effect could be observed at low effector-to-target (E:T) ratios and in the majority of cases without additional activation of autologous T cells by IL-2. Even in samples derived from patients heavily pretreated with different chemotherapy regimens, strong cytotoxic effects of bscCD193CD3 could be observed. The addition of bscCD193CD3 to patients' cells resulted in an upregulation of activation-specific cell surface antigens on autologous T cells and elevated levels of CD95 on lymphoma B cells. Although anti-CD95 antibody CH-11 failed to induce apoptosis in lymphoma cells, we provide evidence that B-CLL cell depletion by bscCD3CD3 is mediated at least in part by apoptosis via the caspase pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1999. CA: Cancer J Clin 1999; 49: 8–31, 31.
Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJS . Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukemia. Br J Haematol 1996; 93: 151–153.
Österborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574.
Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo V et al. Treatment of B-cell non-Hodgkin's lymphoma with anti-CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol 2001; 37: 13–25.
Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195.
Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R et al. Rituximab in the treatment of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326–1331.
Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A . Cytokine-release syndrome in patients with B-Cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 1999; 94: 2217–2224.
Clynes RA, Towers TL, Presta LG, Ravetch JV . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443–446.
Dyer MJ, Hale G, Hayhoe FG, Waldmann H . Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431–1439.
van Spriel AB, van Ojik HH, van De Winkel JG . Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000; 21: 391–397.
Weiner GJ, De Gast GC . Bispecific monoclonal antibody therapy of B-cell malignancy. Leukemia Lymphoma 1995; 16: 199–207.
Tedder TF, Zhou LJ, Engel P . The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 1994; 15: 437–442.
Tedder TF, Inaoki M, Sato S . The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6: 107–118.
Demanet C, Brissinck J, De Jonge J, Thielemans K . Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 1996; 87: 4390–4398.
Haagen IA, Geerars AJ, de Lau WB, Bast BJ, De Gast BC . The efficacy of CD3 × CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood 1995; 85: 3208–3212.
Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ . Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 2000; 96: 3544–3552.
Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B et al. Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: costimulation via CD28 prevents ‘veto’ apoptosis of antibody-targeted cytotoxic T cells. Blood 1998; 92: 4750–4757.
Nitta T, Sato K, Yagita H, Okumura K, Ishii S . Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335: 368–371.
Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87: 1463–1469.
De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A et al. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 1995; 4: 433–437.
Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 89: 2042–2047.
Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD et al. Phase 1 trial of the novel bispecific molecule H22 × Ki-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100: 3101–3107.
Kostelny SA, Cole MS, Tso JY . Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148: 1547–1553.
Lanzavecchia A, Scheidegger D . The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1987; 17: 105–111.
Mallender WD, Voss EJ . Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994; 269: 199–206.
Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95: 2098–2103.
Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690–697.
Blagosklonny M . Treatment with inhibitors of caspases that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia 2001; 15: 936–941.
Mack M, Riethmüller G, Kufer P . A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92: 7021–7025.
Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2001; 277: 2073–2080.
Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS . The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000; 60: 6259–6265.
Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR . Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 2001; 61: 1138–1143.
Tesch H, Engert A, Manzke O, Diehl V, Bohlen H . Treatment of patients with malignant lymphomas with monoclonal antibodies. Bone Marrow Transplant 2000; 26(Suppl 2): S50–S53.
Treon SP, Anderson KC . The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27: 79–85.
Ayanlar-Batuman O, Ebert E, Hauptman SP . Defective inter-leukin-2 production and responsiveness by T cells in patients with chronic lymphocytic leukemia of B cell variety. Blood 1986; 67: 279–284.
Bartik MM, Welker D, Kay NE . Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 1998; 25: 27–33.
Kay NE, Kaplan ME . Defective T cell responsiveness in chronic lymphocytic leukemia: analysis of activation events. Blood 1986; 67: 578–581.
Prieto A, Garcia-Suarez J, Reyes E, Lapena P, Hernandez M, Alvarez-Mon M . Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals. Exp Hematol 1993; 21: 1563–1569.
Zaknoen SL, Kay NE. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev 1990; 4: 165–174.
Shimoni A, Marcus H, Dekel B, Shkarchi R, Arditti F, Shvidel L et al. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera. Cancer Res 1999; 59: 5968–5974.
Natarajan S, Kay NE, Yannelli JR . In vitro propagation of anti-tumor lymphocytes derived from the peripheral blood mononuclear cells of patients with B-chronic lymphocytic leukemia. Blood 1996; 99: 589a.
Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143.
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, von Fliedner V et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993; 53: 4310–4314.
Manzke O, Berthold F, Huebel K, Tesch H, Diehl V, Bohlen H . CD3 × CD19 bispecific antibodies and CD28 bivalent antibodies enhance T- cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int J Cancer 1999; 80: 715–722.
Haagen IA, van de Griend R, Clark M, Geerars A, Bast B, de Gast B . Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19). Clin Exp Immunol 1992; 90: 368–375.
Haagen IA, Geerars AJ, de Lau WB, Clark MR, van de Griend RJ, Bast BJ et al. Killing of autologous B-lineage malignancy using CD3 × CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 1994; 84: 556–563.
Cochlovius B, Kipriyanov SM, Stassar MJ, Christ O, Schuhmacher J, Strauss G et al. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells. J Immunol 2000; 165: 888–895.
Lehmann C, Zeis M, Schmitz N, Uharek L . Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000; 96: 594–600.
Renner C, Hartmann F, Pfreundschuh M . Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Cancer Immunol Immunother 1997; 45: 184–186.
Bauer S, Renner C, Juwana JP, Held G, Ohnesorge S, Gerlach K et al. Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res 1999; 59: 1961–1965.
Russell JH, Ley TJ . Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323–370.
Hennino A, Berard M, Casamayor-Palleja M, Krammer PH, Defrance T . Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J Immunol 2000; 165: 3023–3030.
Barry M, Heibein JA, Pinkoski MJ, Lee SF, Moyer RW, Green DR et al. Granzyme B short-circuits the need for caspase 8 activity during granule-mediated cytotoxic T-lymphocyte killing by directly cleaving Bid. Mol Cell Biol 2000; 20: 3781–3794.
Thomas DA, Du C, Xu M, Wang X, Ley TJ . DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 2000; 12: 621–632.
Kitada S, Zapata JM, reeff M, Reed JC . Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995–1004.
Jones DT, Ganeshaguru K, Virchis AE, Folarin NI, Lowdell MW, Mehta AB et al. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 2001; 98: 2800–2807.
Roue G, Lancry L, Duquesne F, Salaun V, Troussard X, Sola B . Upstream mediators of the Fas apoptotic transduction pathway are defective in B-chronic lymphocytic leukemia. Leukemia Res 2001; 25: 967–980.
Osorio LM, Aguilar-Santelises M, De Santiago A, Hachiya T, Mellstedt H, Jondal M . Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol 2001; 66: 342–346.
Acknowledgements
We thank Dr Peter Trinder and Dr Thorsten Stuehmer for critical reading of the manuscript. This investigation was supported in part by the Deutsche Forschungsgemeinschaft, Klinische Forschergruppe, Grant No. KFO 105/1.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Löffler, A., Gruen, M., Wuchter, C. et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17, 900–909 (2003). https://doi.org/10.1038/sj.leu.2402890
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402890
Keywords
This article is cited by
-
Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia
Cancer Immunology, Immunotherapy (2023)
-
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
Bone Marrow Transplantation (2023)
-
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
Cellular & Molecular Immunology (2022)
-
The present and future of immunocytokines for cancer treatment
Cellular and Molecular Life Sciences (2022)
-
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Journal of Hematology & Oncology (2021)